moleculin biotech, INC. (NASDAQ:MBRX) Files An 8-K Entry into a Material Definitive AgreementItem 1.01.
On June 20, 2018, Moleculin Biotech, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”) for the sale by the Company of 1,092,636 shares (the “Common Shares”) of the Company’s common stock (the “Common Stock”), at a purchase price of $2.105 per share. Concurrently with the sale of the Common Shares, to the Purchase Agreement the Company also sold warrants to purchase 710,212 shares of Common Stock (the “Warrants”). The Company sold the Common Shares and Warrants for aggregate gross proceeds of approximately $2.3 million. Subject to certain beneficial ownership limitations, the Warrants will be initially exercisable on the six-month anniversary of the issuance date at an exercise price equal to $2.02 per share of Common Stock, subject to adjustments as provided under the terms of the Warrants. The Warrants are exercisable for five years from the initial exercise date. The closing of the sales of these securities under the Purchase Agreement is expected to occur on June 22, 2018.
The Company estimates that the net proceeds from the transactions will be approximately $2.1 million after deducting certain fees due to the placement agent and the Company’s estimated transaction expenses. The net proceeds received by the Company from the transactions will be used for its planned clinical trials, preclinical programs, for other research and development activities and for general corporate purposes.
The Common Shares were offered and sold by the Company to an effective shelf registration statement on Form S-3, which was filed with the Securities and Exchange Commission (the “SEC”) on July 24, 2017 and subsequently declared effective on August 21, 2017 (File No. 333-219434) (the “Registration Statement”), and the base prospectus contained therein. The Company filed a prospectus supplement with the SEC on June 21, 2018 in connection with the sale of the Common Shares.
The Warrants and the shares issuable upon exercise of the Warrants were sold without registration under the Securities Act of 1933 (the “Securities Act”) in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.
The representations, warranties and covenants contained in the Purchase Agreement were made solely for the benefit of the parties to the Purchase Agreement. In addition, such representations, warranties and covenants (i) are intended as a way of allocating the risk between the parties to the Purchase Agreement and not as statements of fact, and (ii) may apply standards of materiality in a way that is different from what may be viewed as material by stockholders of, or other investors in, the Company. Accordingly, the Purchase Agreement is included with this filing only to provide investors with information regarding the terms of transaction, and not to provide investors with any other factual information regarding the Company. Stockholders should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Purchase Agreement, which subsequent information may or may not be fully reflected in public disclosures.
The Company also entered into a placement agent agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (“Roth”), to which Roth agreed to serve as exclusive placement agent for the issuance and sale of the Common Shares and Warrants. The Company has agreed to pay Roth an aggregate fee equal to 6.5% of the gross proceeds received by the Company from the sale of the securities in the transactions. to the Placement Agency Agreement, the Company also agreed to grant to Roth or its designees warrants to purchase up to 3% of the aggregate number of shares of Common Stock sold in the transactions (the “Roth Warrants”). The Roth Warrants have substantially the same terms as the Warrants, except that the Roth Warrants have an exercise price of $2.3155 and will expire on June 20, 2023. The Roth Warrants and the shares issuable upon exercise of the Roth Warrants will be issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and in reliance on similar exemptions under applicable state laws. The Company will also reimburse Roth for its expenses of $50,000.
The forms of the Purchase Agreement, the Warrant and the Placement Agency Agreement are filed as Exhibits 10.1, 4.1 and 1.1, respectively, to this Current Report on Form 8-K. The foregoing summaries of the terms of these documents are subject to, and qualified in their entirety by, such documents, which are incorporated herein by reference.
Item 3.02 Unregistered Sales of Equity Securities.
The information contained above in Item 1.01 related to the Warrants and the Roth Warrants is hereby incorporated by reference into this Item 3.02.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Moleculin Biotech, Inc. ExhibitEX-1.1 2 tv496929_ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 PLACEMENT AGENCY AGREEMENT June 20,…To view the full exhibit click here
About moleculin biotech, INC. (NASDAQ:MBRX)
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of September 30, 2016, it had not generated any revenue from its operations.
